Arcutis Biotherapeutics, Inc. (ARQT)
23.90
+0.24
(+1.01%)
USD |
NASDAQ |
Sep 04, 16:00
24.50
+0.60
(+2.51%)
Pre-Market: 20:00
Arcutis Biotherapeutics Research and Development Expense (Quarterly) : 20.36M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 20.36M |
| March 31, 2026 | 30.63M |
| December 31, 2025 | 20.45M |
| September 30, 2025 | 19.60M |
| June 30, 2025 | 19.45M |
| March 31, 2025 | 17.54M |
| December 31, 2024 | 14.48M |
| September 30, 2024 | 19.50M |
| June 30, 2024 | 19.30M |
| March 31, 2024 | 23.14M |
| December 31, 2023 | 23.78M |
| September 30, 2023 | 26.24M |
| June 30, 2023 | 25.22M |
| March 31, 2023 | 35.34M |
| December 31, 2022 | 33.88M |
| September 30, 2022 | 69.73M |
| Date | Value |
|---|---|
| June 30, 2022 | 38.20M |
| March 31, 2022 | 40.62M |
| December 31, 2021 | 52.56M |
| September 30, 2021 | 40.60M |
| June 30, 2021 | 30.76M |
| March 31, 2021 | 21.63M |
| December 31, 2020 | 27.37M |
| September 30, 2020 | 32.74M |
| June 30, 2020 | 30.01M |
| March 31, 2020 | 25.18M |
| December 31, 2019 | 10.76M |
| September 30, 2019 | 12.35M |
| June 30, 2019 | 7.213M |
| March 31, 2019 | 6.203M |
| December 31, 2018 | 5.347M |
| September 30, 2018 | 7.081M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Insmed, Inc. | 210.03M |
| Emergent BioSolutions, Inc. | 9.20M |
| Exelixis, Inc. | 211.99M |
| Vertex Pharmaceuticals, Inc. | 993.80M |